CervoMed Inc.
6.88+0.14 (+2.08%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · CRVO · USD
Key Stats
Market Cap
63.66MP/E (TTM)
-Basic EPS (TTM)
-2.63Dividend Yield
0%Recent Filings
8-K
Investor presentation disclosed
CervoMed Inc. disclosed a new investor presentation on October 22, 2025, covering its business, clinical studies, development plans, and financial position, now available on its website under Investors – Events and Presentations. The company may use this material at upcoming conferences and meetings, though it warns the info is summary and not filed under securities laws. No specific updates or figures were detailed in the filing.
8-K
Positive neflamapimod DLB trial data
CervoMed released new Phase 2b RewinD-LB trial data on October 8, 2025, showing neflamapimod significantly improved CDR-SB scores versus placebo in DLB patients with low AD co-pathology likelihood, based on within-subject analysis. Reductions in plasma GFAP biomarker correlated with better clinical outcomes, signaling slowed neurodegeneration. The company awaits FDA feedback on Phase 3 design this quarter. Yet, replication in larger trials remains key.
8-K
Neflamapimod reduces LB worsening
CervoMed Inc. announced second quarter 2025 financial results alongside 32-week data from the Phase 2b RewinD-LB trial extension, revealing neflamapimod's substantial reduction in clinically significant worsening versus control. The benefit sharpened further in patients with minimal Alzheimer's co-pathology. Data bolsters neflamapimod's potential for dementia with Lewy bodies. Financial specifics remain undisclosed in the filing.
10-Q
Q2 FY2025 results
CervoMed's Q2 2025 grant revenue fell to $1.8M from $3.3M y/y, while R&D expenses climbed 35% to $5.1M and G&A rose 30% to $3.3M, driving an operating loss of $6.6M—up from $3.0M last year—and a net loss of $6.3M, or $0.70 per diluted share on 8.95M shares. YTD through June 30, losses widened to $11.2M from $4.8M y/y, with cash burn hitting $10.4M from operations and no capex disclosed for free cash flow. Cash and equivalents dipped to $8.3M, but total liquidity held at $33.5M including marketable securities, bolstered by $4.6M from a May stock sale under the at-the-market program. The RewinD-LB trial wrapped with NIA grant funds nearing exhaustion at $2.9M remaining. Former COO's July separation added $0.6M in severance. Ongoing litigation risks could drain resources further.
8-K
CervoMed posts investor presentation
CervoMed Inc. disclosed business, clinical studies, development plans, and financial position details via a presentation posted on its website on August 5, 2025, under Item 7.01 for Regulation FD compliance. The materials, accessible at www.cervomed.com in the Investors section, may be used in investor meetings with minor tweaks. No specific updates or figures were detailed in the filing. This routine disclosure aids transparency without new commitments.
ANVS
Annovis Bio, Inc.
2.20+0.10
BIVI
BioVie Inc.
1.80-0.06
CBIO
Crescent Biopharma, Inc.
12.50+0.00
HALB
Halberd Corp.
0.00+0.00
IBO
Impact BioMedical, Inc.
0.57-0.01
LGVN
Longeveron Inc.
0.89-0.04
NERV
Minerva Neurosciences, Inc
4.23-0.37
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
NWBO
Northwest Biotherapeutics, Inc.
0.23-0.02